Under construction – not a live service
Sign in
Taking peoplePhase 3

Tests higher dulaglutide doses in children with type 2 diabetes

Tests two dulaglutide doses in children aged 10 to 17 with type 2 diabetes.

Plain-language title generated from the registry record
Registry title: A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)

Key facts

Where
Ciudad Madero, Puebla City, Tampico, Tlalpan, and Veracruz, MexicoSee the 5 sites
Phase
Phase 3

AI summary: who the study is looking for

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for children and teenagers aged 10 to 17 with type 2 diabetes who weigh at least 50 kg (110 lb) and have a high body mass index. They would take dulaglutide.

Age
10 to 17 years
Sex
Boys and girls can both join.
Disease stage
Type 2 diabetes treated with diet, exercise and metformin and/or basal insulin. Body mass index above the 85th percentile.
Earlier treatment
The metformin and/or basal insulin dose must have been stable for at least 8 weeks before screening.

Main reasons for not taking part

  • Type 1 diabetes
  • Other glucose-lowering medicines (besides metformin, basal insulin or dulaglutide) in the 8 weeks before screening
  • Diabetic ketoacidosis or hyperosmolar syndrome after the type 2 diabetes diagnosis
  • Severe low blood sugar or unawareness of low blood sugar in the last 6 months
  • Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2

Read by machine on 12 November 2026.

Could this be for you?

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 10 and 17 years old?

Source: NCT06739122, who can take part

Where in Mexico

  • Centro de Estudios de Investigacion Metabolicos y CardiovascularesCiudad Madero, MexicoContact: Rafael Violante Ortiz (principal investigator)Not yet recruiting
  • Hospital Angeles (HA) - PueblaPuebla City, MexicoContact: Margarita Barrientos (principal investigator)Not yet recruiting
  • Clínica CemainTampico, MexicoContact: Ricardo Salas Flores (principal investigator)Not yet recruiting
  • Innovacion y Desarrollo de Estrategias en Salud SA de CVTlalpan, MexicoContact: Maria Fernanda Castilla Peon (principal investigator)Not yet recruiting
  • Arké SMO S.A de C.VVeracruz, MexicoContact: Maria del Carmen Ramon Ramirez (principal investigator)Not yet recruiting

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Trial details

Who runs it
Eli Lilly and Company
Trial code
NCT06739122
Record updated
7 August 2026
Original description
The main purpose of this study is to evaluate additional dosing options for dulaglutide in pediatric participants with Type 2 Diabetes. Participation in this study will last about 8 months.Read full original descriptionShow less

A Phase 3, Open-Label, Multicenter, Single-Arm Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of Dulaglutide 3.0 mg and 4.5 mg in Pediatric Participants 10 to Less Than 18 Years of Age With Type 2 Diabetes Mellitus

The main purpose of this study is to evaluate additional dosing options for dulaglutide in pediatric participants with Type 2 Diabetes. Participation in this study will last about 8 months.

Inclusion: Have Type 2 diabetes treated with diet and exercise and metformin and/or basal insulin. Metformin and/or basal insulin dose must be stable for at least 8 weeks prior to screening; Have a body weight ≥50 kilograms (kg) and Body Mass Index (BMI) of >85th percentile.

Exclusion: Have prior chronic, recurrent, or idiopathic pancreatitis, or known gallbladder disease; Have been treated with prescription drugs or over-the-counter medications that promote weight loss within 8 weeks prior to screening; Have Type 1 diabetes; After the Type 2 diabetes diagnosis, have a history of diabetic ketoacidosis or hyperosmolar syndrome; Have family or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN2); Have received treatment with any glucose-lowering agent(s) other than metformin, basal insulin, or dulaglutide within 8 weeks prior to screening; Have had ≥1 episode of severe hypoglycemia and/or ≥1 episode of hypoglycemic unawareness within the last 6 months.

ClinicalTrials.gov NCT06739122